

Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 29.09.2023
3.2	14.04.2025	25805-00024	Date of first issue: 27.10.2014

SECTION 1: Identification of the substance/mixture and of the company/undertaking**1.1 Product identifier**

Trade name : Vaniprevir Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised againstUse of the Sub-
stance/Mixture : PharmaceuticalRecommended restrictions
on use : Not applicable**1.3 Details of the supplier of the safety data sheet**Company : MSD
117 16th Road
1685 Halfway house, Midrand, South Africa

Telephone : +27 11 655 3000

E-mail address of person
responsible for the SDS : EHSDATASTEWARD@msd.com**1.4 Emergency telephone number**

+1-908-423-6000

SECTION 2: Hazards identification**2.1 Classification of the substance or mixture****Classification (REGULATION (EC) No 1272/2008)**Specific target organ toxicity - repeated
exposure, Category 2 H373: May cause damage to organs through pro-
longed or repeated exposure.**2.2 Label elements****Labelling (REGULATION (EC) No 1272/2008)**

Hazard pictograms :



Signal word : Warning

Hazard statements : H373 May cause damage to organs through prolonged or
repeated exposure.Precautionary statements : **Prevention:**

Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 29.09.2023
3.2	14.04.2025	25805-00024	Date of first issue: 27.10.2014

P260 Do not breathe dust.

Response:

P314 Get medical advice/ attention if you feel unwell.

Hazardous components which must be listed on the label:

Vaniprevir

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients**3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Vaniprevir	923590-37-8	STOT RE 2; H373 (gallbladder, Liver)	>= 10 - < 20

For explanation of abbreviations see section 16.

SECTION 4: First aid measures**4.1 Description of first aid measures**

- | | | |
|----------------------------|---|---|
| General advice | : | In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| If inhaled | : | If inhaled, remove to fresh air.
Get medical attention if symptoms occur. |
| In case of skin contact | : | Wash with water and soap.
Get medical attention if symptoms occur. |
| In case of eye contact | : | If in eyes, rinse well with water.
Get medical attention if irritation develops and persists. |

Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 29.09.2023
3.2	14.04.2025	25805-00024	Date of first issue: 27.10.2014

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

May cause damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures**5.1 Extinguishing media**

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 29.09.2023
3.2	14.04.2025	25805-00024	Date of first issue: 27.10.2014

SECTION 6: Accidental release measures**6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage**7.1 Precautions for safe handling**

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.

Vaniprevir Formulation

Version 3.2 Revision Date: 14.04.2025 SDS Number: 25805-00024 Date of last issue: 29.09.2023
 Date of first issue: 27.10.2014

Hygiene measures : Take care to prevent spills, waste and minimize release to the environment.
 : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:
 Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection**8.1 Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Vaniprevir	923590-37-8	TWA	300 µg/m ³	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
Polyethylene glycol castor oil	Workers	Inhalation	Long-term systemic effects	16,4 mg/m ³
	Workers	Skin contact	Long-term systemic effects	4,67 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	2,9 mg/m ³
	Consumers	Skin contact	Long-term systemic effects	1,67 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	1,67 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Polyethylene glycol castor oil	Fresh water	0,000 mg/l
	Freshwater - intermittent	0,0661 mg/l
	Marine water	0,000 mg/l
	Marine water - intermittent	0,00661 mg/l
	Fresh water sediment	0,0129 mg/kg dry weight (d.w.)
	Marine sediment	0,00129 mg/kg dry weight (d.w.)
	Soil	0,00258 mg/kg

Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 29.09.2023
3.2	14.04.2025	25805-00024	Date of first issue: 27.10.2014

dry weight (d.w.)

8.2 Exposure controls

Engineering measures

Ensure adequate ventilation, especially in confined areas.
Minimize workplace exposure concentrations.
Apply measures to prevent dust explosions.
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

Eye/face protection : Wear the following personal protective equipment:
Safety goggles

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Skin and body protection : Skin should be washed after contact.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance : powder
Colour : tan
Odour : odourless
Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 29.09.2023
3.2	14.04.2025	25805-00024	Date of first issue: 27.10.2014

Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Density	:	1 g/cm ³
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

9.2 Other information

Molecular weight	:	No data available
Particle size	:	No data available

SECTION 10: Stability and reactivity**10.1 Reactivity**

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
---------------------	---	--

10.4 Conditions to avoid

Conditions to avoid	:	Heat, flames and sparks.
---------------------	---	--------------------------

Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 29.09.2023
3.2	14.04.2025	25805-00024	Date of first issue: 27.10.2014

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information**11.1 Information on toxicological effects**

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**Vaniprevir:**

Acute oral toxicity : LD50 (Rat): > 750 mg/kg
Remarks: No adverse effect has been observed in acute toxicity tests.

LD0 (Dog): > 300 mg/kg
Remarks: No adverse effect has been observed in acute toxicity tests.

LD50 (Mouse): > 2.000 mg/kg
Remarks: No mortality observed at this dose.

Skin corrosion/irritation

Not classified based on available information.

Components:**Vaniprevir:**

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Vaniprevir:**

Species : Bovine cornea
Method : Bovine cornea (BCOP)
Result : Mild eye irritation

Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 29.09.2023
3.2	14.04.2025	25805-00024	Date of first issue: 27.10.2014

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Vaniprevir:**

Test Type	:	Local lymph node assay (LLNA)
Species	:	Mouse
Result	:	negative

Germ cell mutagenicity

Not classified based on available information.

Components:**Vaniprevir:**

Genotoxicity in vitro	:	Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative
		Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Alkaline elution assay Test system: rat hepatocytes Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative

Carcinogenicity

Not classified based on available information.

Components:**Vaniprevir:**

Species	:	Rat, male and female
Application Route	:	Oral
Activity duration	:	104 Weeks
	:	>= 120 mg/kg body weight
Result	:	negative
Species	:	Mouse
Application Route	:	Oral
Activity duration	:	6 Months
	:	>= 300 mg/kg body weight
	:	75 mg/kg body weight
Result	:	negative

Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 29.09.2023
3.2	14.04.2025	25805-00024	Date of first issue: 27.10.2014

Target Organs : gallbladder

Reproductive toxicity

Not classified based on available information.

Components:**Vaniprevir:**

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, male and female
Application Route: Oral
General Toxicity - Parent: NOAEL: \geq 250 mg/kg body weight
Result: No effects on fertility

Effects on foetal development : Test Type: Development
Species: Rat, female
Application Route: Oral
General Toxicity Maternal: NOAEL: 120 mg/kg body weight
Developmental Toxicity: LOAEC F1: 180 mg/kg body weight
Symptoms: No specific developmental abnormalities
Result: negative

Test Type: Development
Species: Rabbit, female
Application Route: Oral
General Toxicity Maternal: NOAEL: 120 mg/kg body weight
Developmental Toxicity: NOAEL F1: \geq 240 mg/kg body weight
Symptoms: No specific developmental abnormalities
Result: negative

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:**Vaniprevir:**

Exposure routes : Ingestion
Target Organs : gallbladder, Liver
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Vaniprevir:**

Species : Rat
NOAEL : 120 mg/kg
LOAEL : 360 mg/kg
Application Route : Oral

Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 29.09.2023
3.2	14.04.2025	25805-00024	Date of first issue: 27.10.2014

Exposure time	:	6 Months
Target Organs	:	Liver
Species	:	Dog
NOAEL	:	15 mg/kg
LOAEL	:	30 mg/kg
Application Route	:	Oral
Exposure time	:	9 Months
Target Organs	:	Liver, gallbladder
Symptoms	:	Gastrointestinal disturbance
Species	:	Mouse
NOAEL	:	150 mg/kg
LOAEL	:	300 mg/kg
Application Route	:	Oral
Exposure time	:	90 d
Target Organs	:	Liver, Kidney, Gastrointestinal tract, Heart, gallbladder, Stomach

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Vaniprevir:**

Ingestion	:	Symptoms: stomach discomfort, Diarrhoea, Nausea, Headache
-----------	---	---

SECTION 12: Ecological information**12.1 Toxicity****Components:****Vaniprevir:**

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 4 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility LC50 (Americamysis): > 4 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035 Remarks: No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility NOEC (Pseudokirchneriella subcapitata (green algae)): 4 mg/l Exposure time: 72 h

Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 29.09.2023
3.2	14.04.2025	25805-00024	Date of first issue: 27.10.2014

Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC : 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

12.2 Persistence and degradability**Components:****Vaniprevir:**

Biodegradability : Result: not rapidly degradable
Method: OECD Test Guideline 314

12.3 Bioaccumulative potential**Components:****Vaniprevir:**

Partition coefficient: n-octanol/water : log Pow: 4,12

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment**Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects**Product:**

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations**13.1 Waste treatment methods**

Product : Dispose of in accordance with local regulations.

Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 29.09.2023
3.2	14.04.2025	25805-00024	Date of first issue: 27.10.2014

According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information**14.1 UN number**

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA (Cargo) : Not regulated as a dangerous good

IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 29.09.2023
3.2	14.04.2025	25805-00024	Date of first issue: 27.10.2014

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information**15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture****The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H373 : May cause damage to organs through prolonged or repeated exposure if swallowed.

Full text of other abbreviations

STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office

Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 29.09.2023
3.2	14.04.2025	25805-00024	Date of first issue: 27.10.2014

of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

STOT RE 2

H373

Classification procedure:

Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN